RedHill Biopharma’s Potential Crohn’s Treatment, RHB-104, Likely to Receive US Patent

RedHill Biopharma’s Potential Crohn’s Treatment, RHB-104, Likely to Receive US Patent
RedHill Biopharma recently announced that it received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for its patent covering RHB-104, a new oral combination drug currently being assessed in clinical trials for Crohn’s disease treatment. RedHill is an Israeli biopharmaceutical company focusing on the development of orally administered drugs for inflammatory and gastrointestinal diseases, such as

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

2 comments

  1. Sherine says:

    I have been following since quite sometime the progress of the RHb 104 for Crohn’s disease as i am quite optimistic about Map hypothesis and hope it materialize. What is not clear is when the medication will be in the market? If ever.. It gives me hope of a cure ..

  2. kathy britt says:

    I am very optimistic about this drug because I’ve been following the research on MAP and just know there’s validity to this theory. I just want this disease cured or managed safely giving our kids a chance at life. How do we find out about a release date?

Leave a Comment

Your email address will not be published. Required fields are marked *